ClinicalTrials.gg
Active, not recruitingNCT06143709Updated Aug 18, 2026

Precision PCI Registry

An observational study in Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by University of Florida. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by University of Florida · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,643
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Coronary Artery Disease by University of Florida — 6 open to participants now, 8 under way, none of them phase 3. Coronary Artery Disease · University of Florida.

Started
2020
with 1 other
Observational
5 of 40
1 open now
Registered
34th of 40
by date

Among the 40 studies in Coronary Artery Disease by University of Florida, this one is one of 2 that started in 2020, is one of 5 observational ones, and was the 34th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

6 of the 40 studies in Coronary Artery Disease by University of Florida are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Coronary Artery Disease by University of Florida, or all of them as a file.
02

Study summary

The feasibility and clinical benefit of using a patient's genotype to guide antiplatelet therapy prescribing has been demonstrated. However, a more precise understanding of who to genotype, what to include on a genetic testing panel, and how to change antiplatelet therapy based on genotype results and other patient-specific factors is needed to optimize the impact of genotype-guided antiplatelet therapy on patient outcomes.

The Precision PCI registry is a collaboration between the University of Florida, Gainesville and Jacksonville, USA, the University of North Carolina, Chapel Hill, USA, and University of Maryland, Baltimore, USA. This registry will include a diverse population of patients who undergo Percutaneous Coronary Intervention and clinical CYP2C19 genotyping, assess clinical outcomes over 12 months and collect DNA samples for additional genotyping, and conduct pharmacodynamic analysis of platelet function in a subset of patients.

Objectives of the study:

  1. Define the influence of African ancestry and other patient-specific factors on clinical outcomes with genotype-guided antiplatelet therapy following PCI in a real-world setting
  2. Evaluate the safety and effectiveness of genotype-guided de-escalation of antiplatelet therapy (i.e., switching to less potent antiplatelet therapy) after PCI in a real-world setting
  3. Elucidate the effect(s) of genotypes beyond CYP2C19 on platelet reactivity and clinical outcomes with clopidogrel after PCI
Read the detailed description

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is the standard of care after percutaneous coronary intervention (PCI) to reduce the risk of atherothrombotic events. Prasugrel and ticagrelor are preferred over clopidogrel in patients with an acute coronary syndrome but are associated with greater bleeding risk. The cytochrome P450 (CYP)2C19 enzyme is essential for metabolism of clopidogrel (a prodrug) to its pharmacologically active form. Approximately 30% of the U.S. population carries a CYP2C19 loss-of-function (LOF) allele that reduces the bioactivation and effectiveness of clopidogrel, but not prasugrel or ticagrelor, after PCI.

Previous studies have demonstrated the feasibility and effectiveness of incorporating CYP2C19 genotyping into clinical care to guide DAPT, with prasugrel or ticagrelor prescribed in patients with a CYP2C19 LOF allele. However, the influence of key patient-specific factors on outcomes with genotype-guided DAPT (notably African ancestry, comorbidities that impact clopidogrel effectiveness, and genotypes beyond CYP2C19) has not been defined but is critical to understand in order to optimize the clinical impact of genotype-guided DAPT. Moreover, the impact on clinical outcomes of using CYP2C19 genotype to guide de-escalation from more potent agents (e.g., prasugrel or ticagrelor) to clopidogrel in patients without a LOF allele, which has become highly clinically relevant due to more frequent initial use of prasugrel or ticagrelor after acute coronary syndrome and PCI, has not been investigated in a diverse, real-world clinical setting.

The long-term goal of this line of research is to optimize a precision medicine DAPT strategy that improves outcomes after PCI. The investigators hypothesize that multiple clinical and genetic factors jointly contribute to the effectiveness and safety of CYP2C19 LOF allele-guided selection of DAPT after PCI in a real-world clinical setting. This hypothesis will be tested by conducting a multi-center, observational study of 1,500 patients with PCI and clinical CYP2C19 genetic testing.

Aim 1: Define the influence of African ancestry and other patient-specific factors on clinical outcomes with CYP2C19 genotype-guided DAPT after PCI in a real-world setting

Aim 2: Evaluate the safety and effectiveness of CYP2C19 genotype-guided de-escalation of DAPT following PCI in a real-world setting

Aim 3: Elucidate the effect(s) of genetic variants beyond CYP2C19 LOF alleles on platelet reactivity and clinical outcomes with clopidogrel after PCI

A total of 1500 patients will be enrolled. Their data will be added to an existing cohort of approximately 4500 patients to address these aims.

Baseline data from the PCI admission will include:

  • PCI indication
  • Angiographic and procedural features (e.g. location of PCI, stent type)
  • CYP2C19 genotype
  • Discharge diagnoses
  • Medications on admission, during hospitalization, and at discharge
  • Self-reported race
  • Socioeconomic status (including education, income and occupation)
  • Health insurance type

Follow-up Data:

Patient follow-up will occur at 1, 6, and 12 months after PCI or until DAPT discontinuation via telephone call and EHR review to assess for hospitalizations and medication changes.

Data Management:

Data will be stored electronically in a secured database that is only accessible to study investigators. Quality assurance procedures will include use of a data dictionary, data checks ensure compliance with predefined rules for data ranges and checks for missing data. Hospitalization records will be reviewed by independent cardiologists to verify atherothrombotic and bleeding events. Deaths will be assessed by query of the National Death Index (NDI) and North Carolina state death index.

03

Conditions studied

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention

Keywords

  • CYP2C19 Genotype
  • Percutaneous coronary intervention
  • Clopidogrel
  • Plavix
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target patient population will be male or female adults (age 18 years), of any race or ethnicity, who undergo PCI and clinical CYP2C19 genotyping, and are treated with clopidogrel, prasugrel, or ticagrelor in addition to aspirin.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Underwent percutaneous coronary intervention for any indication
  • Had clinical CYP2C19 genotyping
  • Treated with dual antiplatelet therapy including clopidogrel, prasugrel, or ticagrelor plus aspirin or
  • Treated with a combination of a P2Y12 inhibitor i.e. clopidogrel, prasugrel or ticagrelor plus an oral anticoagulant.

Exclusion criteria

Exclusion Criteria:

  • Managed surgically
  • Treated with thrombolysis within 48 hours
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,643 participants (actual)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Precision PCI Prospective Cohort

    Patients who have undergone PCI and clinical CYP2C19 genotyping

    Other: DNA sample collection

Interventions

  • OtherDNA sample collection

    Patients will be asked to provide a blood or mouth wash sample for DNA extraction

06

What researchers measure

Primary outcomes

  1. Major atherothrombotic events

    Composite of death, myocardial infarction, ischemic stroke, stent thrombosis, and revascularization for unstable angina

    Time frame: 12 months

Secondary outcomes

  1. Net clinical benefit

    Major atherothrombotic events or clinically significant bleeding

    Time frame: 12 months

  2. Major adverse cardiovascular events

    Composite of cardiovascular death, myocardial infarction, ischemic stroke, and stent thrombosis

    Time frame: 12 months

  3. Clinically significant bleeding

    Moderate or severe/life-threatening bleeding according to GUSTO criteria

    Time frame: 12 months

  4. All cause death

    Death from any cause

    Time frame: 12 months

  5. Cardiovascular death

    Death resulting from myocardial infarction, arrhythmia, heart failure, stroke, or other cardiovascular cause

    Time frame: 12 months

  6. Myocardial infarction

    New ischemic symptoms and troponin elevation

    Time frame: 12 months

  7. Ischemic stroke

    Acute neurologic deficit that lasts over 24 hours and affects the ability to perform daily activities with or without confirmation of imaging

    Time frame: 12 months

  8. Stent thrombosis

    Definite or probable stent thrombosis defined according to the Academic Research Consortium

    Time frame: 12 months

  9. Unstable angina

    Acute ischemic event with no evidence of myocardial infarction and angiographic evidence of new or worsening obstructive coronary disease, or intracoronary thrombus, believed to be responsible for the ischemic symptoms and requiring coronary revascularization

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Ortega-Paz L, Thomas CD, Laudani C, Giordano S, Franchi F, Tunehag KR, Rollini F, Durukan S, Rossi JS, Farahmandsadr M, Stouffer GA, Been L, Keeley EC, Duarte JD, Beitelshees AL, Lee CR, Cavallari LH, Angiolillo DJ. Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated Participants. Clin Pharmacol Ther. 2026 Jan;119(1):168-178. doi: 10.1002/cpt.70045. Epub 2025 Aug 28. PubMed 40875095 ↗

Individual participant data

Plan to share: Yes — We will comply with the NIH Genomic Data Sharing Policy (https://gds.nih.gov/). Institutional Review Board approval and institutional certification will be obtained for the submission of the study data to open-access databases such as the database of Genotypes and Phenotypes (dbGaP). This will be done after all of the individual participant data is collected during the trial, and after deidentification.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: De-identified genomic and phenotype data to be made available by depositing these data in dbGaP as soon as possible but no later than within one year of the completion of the funded project period or upon acceptance of the data for publication.

Access criteria: Data will be available as controlled-access data through dbGaP, in which interested users must submit a Data Use Certification to an appropriate NIH Data Access Committee for approval.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jun 2027, 83 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 83 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
Nov 22, 2023
StartActual
Jul 17, 2020
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06143709
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Jul 17, 2020
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion